openPR Logo
Press release

Oxipit to offer free of charge retrospective CXR quality audit at RSNA

11-24-2021 12:42 PM CET | Health & Medicine

Press release from: Oxipit

At the annual RSNA meeting, the AI medical imaging company will present the new ChestEye Quality AI double reading tool. To showcase vanguard ChestEye Quality capabilities, Oxipit will offer a free-of-charge quality audit for 6 months of retrospective CXR data. ChestEye Quality is already deployed in multiple medical institutions across Europe. With 229.617 images processed, the platform helped to identify 20% extra clinically relevant nodules, as well as numerous missed cases of pneumothorax, device malpositions, consolidations and other clinically significant findings.

ChestEye Quality analyzes final radiologist reports and corresponding CXR images. The platform then identifies impactful clinical errors and missed radiological findings.

In retrospective mode, the platform can effortlessly audit tens or hundreds of thousands of cases. Only suspicious cases are highlighted for an additional radiologist review.

In prospective operations, the platform identifies reporting errors as soon as it receives a CXR image with a corresponding radiologist report. The platform will then automatically notify the clinician on the discrepancies found.

“Multiple clinical studies indicate that double reading is the most effective way to mitigate the risks of misdiagnosis and missed findings. By introducing AI into the quality assurance workflow, ChestEye Quality puts this theory into practice. The platform enables a full real time quality audit, where only clinically relevant cases are flagged for a secondary review. A robust framework of instant notifications via email, coupled with an easy-to-use analytical platform for suspicious case review, make ChestEye a truly impactful tool for routine medical imaging operations”, - noted CEO of Oxipit Gediminas Peksys.

According to Gediminas Peksys, radiology professionals operate in a cognitively intense working environment. In the ‘always-on’ prospective mode, ChestEye Quality provides clinicians with an extra level of diagnostic support.

ChestEye Quality was already tested at multiple pilot locations in Europe, including primary care centers, tertiary hospitals and teleradiology service providers. Based on data from current deployments, up to 0.5% of reports feature clinically significant errors, including missed cases of pneumothorax, device malpositions or consolidations. In current trials, ChestEye Quality also helped medical institutions identify 20% more clinically relevant lung nodules. The platform utilizes smart nodule detection models geared towards minimizing false positives.

“What makes ChestEye Quality unique, is that these errors can be identified and corrected in real time, significantly improving patient outcomes”, - added Gediminas Peksys.

In addition to prospective operations, ChestEye Quality can also operate as a retrospective quality audit tool. In routine clinical practice, where often a random sample of already reported cases are selected for quality audit, ChestEye Quality reviews 100% of previously reported cases - with only suspicious cases highlighted by AI for an additional radiologist review.

“We always start a ChestEye Quality deployment with a retrospective audit. This helps to evaluate the error threshold at the medical institution. The full 6 month CXR case audit can be completed in as few as 7 days”, - said Gediminas Peksys.

According to Gediminas Peksys, a full scale CXR audit may also serve specific use cases - for instance, auditing by medical insurance providers.

“At Oxipit we believe that a competitive edge in Artificial Intelligence is only the first step in AI medical imaging product development. The success lies in defining how software is implemented and used in the clinical workflow, selecting appropriate thresholds and solving user interface challenges. Having a team of data scientists working hand-in-hand with medical doctors, helps Oxipit address real world challenges currently faced by radiology specialists'”, - added Gediminas Peksys.

Oxipit will present ChestEye Quality and other AI medical imaging products at booth #5131 at RSNA on November 28th - December 2nd.

www.oxipit.ai
Sauletekio al. 15-1
Vilnius, Lithuania
+370 625 99148

ABOUT OXIPIT
Oxipit is a computer vision software startup specialized in medical imaging. With a team of award-winning data scientists and medical doctors, the company aims to introduce innovative Artificial Intelligence/Deep Learning breakthroughs to everyday clinical practice.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Oxipit to offer free of charge retrospective CXR quality audit at RSNA here

News-ID: 2472839 • Views:

More Releases from Oxipit

Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
03-02-2023 | Health & Medicine
Oxipit
Oxipit Partners With CARPL To Increase Global Reach Of AI Diagnostic Products
At the European Congress of Radiology in Vienna Oxipit announced that its diagnostic AI solutions will be available on the CARPL platform. CARPL platform users will have access to the full Oxipit AI product portfolio: ChestLink for healthy patient report automation, Quality - for real-time quality assurance and ChestEye - for preliminary reports. The move further builds on Oxipit strategy to increase global reach of company's products. "CARPL is our
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
02-15-2023 | Health & Medicine
Oxipit
Oxipit Secures Brazilian ANVISA Clearance for ChestEye AI Suite
The regulatory approval paves the way for ChestEye deployments in the Brazilian market. The application is already cleared for use in Europe and Australia. The Brazilian Health Regulatory Agency's approval is one of Oxipit steps to increase global reach for company products. "With many future-focused healthcare organizations, LatAm market shows tremendous potential for healthcare AI applications. Oxipit products have already shown strong market traction in the region. The ANVISA certification
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
01-23-2023 | Health & Medicine
Oxipit
Oxipit Closes $4.9M Funding Round To Advance AI Autonomy in Medical Imaging
AI medical imaging company Oxipit closed a $4.9M funding round led by Taiwania Capital and Practica Capital. Angel investors also participated in this round. The funding will help Oxipit advance its development of autonomous AI medical imaging applications and support market expansion into new geographic regions, with particular focus on the United Kingdom. "2022 was a breakthrough year for the Oxipit team. In spring we introduced ChestLink - the first fully
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
11-21-2022 | Health & Medicine
Oxipit
Oxipit Introduces Quality Assurance for MSK, MG, and CT Modalities
AI medical imaging company Oxipit expanded its Quality product suite with quality assurance support for musculoskeletal X-rays, mammography images and lung CT scans. Previously supporting only chest X-rays, the upgraded Quality suite aims to answer all imaging department quality assurance needs with a single product. The updated Quality product will be showcased at RSNA 2022 annual meeting later this month. Oxipit Quality employs AI as the second reader for quality assurance.

All 5 Releases


More Releases for ChestEye

07-18-2022 | Health & Medicine
Oxipit
Chest experts Oxipit and contextflow team up for diagnostic quality assurance
The new partnership aims to mitigate the risk associated with missed findings in CT medical imaging studies. The collaboration will combine Oxipit's ChestEye Quality and contextflow's SEARCH Lung CT products to identify missed findings in CT scans in near-real time. ECR 2022 will offer the first preview of the combined solution, and the first installation will be deployed at Leiden University Medical Center. ChestEye Quality analyzes medical images and corresponding
05-25-2020 | Health & Medicine
Oxipit
Oxipit Receives Patent for Improved AI Lung Cancer Diagnostics
Oxipit, creators of artificial intelligence based radiology imaging suite ChestEye, announces that the European Patent Office has approved their patent application. The innovation allows efficient use of high-resolution chest X-ray images for machine learning model training and is especially relevant for improving lung nodule detection. Modern X-ray equipment produces large images with 16 Megapixel resolution being common. On the other hand, machine learning and artificial intelligence (AI) algorithms are typically optimized
03-05-2020 | Health & Medicine
Oxipit
Oxipit ChestEye secures medical device certification in Australia
The AI medical imaging company has received an Australian Register of Therapeutic Goods Class IIa medical device certificate for ChestEye AI imaging service. Medical device certification paves the way for clinical use of ChestEye in the Australian market. ChestEye imaging suite is already certified by the CE mark. Oxipit received CE certification last February, enabling clinical ChestEye deployment in 32 European countries. "Australia presents a very advanced, well developed healthcare landscape.
01-29-2020 | Health & Medicine
Oxipit
New Oxipit service to aid large scale chest X-ray screening projects
The AI medical imaging company will showcase ChestEye Negative service at Arab Health 2020 conference in Dubai. ChestEye Negative produces preliminary reports for chest X-rays with no abnormality. The service aims to reduce the workload of radiologists, especially in clinical environments, where only a fraction of all studies features an abnormality. It also significantly simplifies large-scale medical screening projects. "Large scale medical surveys - such as tuberculosis screening in migrant populations
11-26-2019 | Health & Medicine
Oxipit
AI vs Radiologists: can AI surpass doctors in reporting accuracy?
A study by the Centre for Advanced Research in Imaging, Neuroscience and Genomics (CARING) found that nearly 80% of AI generated chest X-ray case reports were as accurate as produced by a radiology specialist. Furthermore, AI reports were more accurate in 5% of analyzed patient cases. The study was undertaken using Oxipit ChestEye AI imaging suite. The full study titled The full study titled “Judging the Accuracy and Clinical Validity
07-23-2019 | Health & Medicine
Oxipit
Medical Imaging Company Oxipit raises $1.7M Seed Round to bring AI into Clinical …
Oxipit are the authors of ChestEye AI-powered radiology software suite. Automated AI-based diagnosis and reporting by ChestEye enables radiologists to improve productivity, reduce error-rate, discover overlooked secondary findings and address the shortage and ever-increasing workload of radiology specialists. The round marks the largest investment for medical AI solutions in the Baltic states. It is also one of the largest seed rounds among Baltic startups. In February ChestEye software received CE